Business Experience

RTsafe – Director of Business Development for USA (11/2020 – Present)

RTsafe is a medical technology company that has developed a unique approach to quality assurance that significantly enhances the safety and accuracy of radiotherapy for cancer and other medical conditions. RTsafe’s vision is to help create a world where every radiotherapy intervention is tested on a personalized phantom before the real patient, thus enhancing safety and effectiveness of treatment. The PseudoPatient® head phantom of RTsafe has received an R&D 100 Award from R&D World Magazine as one of the 100 most technologically significant products of 2019.

Responsibilities as Director of Business Development include promoting the success and growth of the company and its products through direct sales in USA, as well as identifying and pursuing fundraising opportunities.

VU Venture Partners – Venture Partner (6/2020 – Present)

VU Venture Partners is a $100M+ multi-stage venture capital fund with a highly scalable approach to investing across Consumer, Enterprise, Fintech, FrontierTech, HealthTech, and PropTech. VU Venture Partners invests in Seed, Series A and follow-on rounds across multiple verticals. Currently sourcing healthcare investment opportunities, covering areas such as digital health, telehealth and drug therapeutics, while achievements include:

  • Invested in 7 companies (incl. Intelage’s $4M Seed Round (trading), Grabango’s $8M SAFE Round (retail), Spyce’s $25M Series A Round (restaurant)) alongside top tier investors (incl. Founders Fund, Khosla Ventures, Maveron, Commerce VC, Qualcom Ventures, Vulcan Capital)
  • Sourced investment opportunities using a structured approach to increasing deal flow velocity in both quantity and quality by doing weekly sprints using multiple deal flow channels
  • Developed investment theses around various industry verticals, reviewed pitch decks, met with startups and investors, and presented top investment opportunities at weekly Partners Meetings and Investment Committees
  • Conducted quantitative and qualitative deep due diligence including: market sizing, team’s ability to execute, go-to-market strategy, key risks, business model, key metrics, financial modeling, competitive landscape, customer and investor interviews, cap table and waterfall analysis, term sheets and investment documents
  • Built a large network across accelerators, VC / PE funds, strategics, and startup founders, and have access to VU’s investor and strategic network

VU General Partners:

  • Andrew Zalasin (Former GP at RRE Ventures for ~20 years, a $1.5B venture fund)
  • J. Skyler Fernandes (Powerlist 100 VC, Founder of leading retail fund Simon Venture Group and Cleveland Avenue, food-focused fund co-founded w/ former CEO of McDonald’s)
  • James Zhang (10+ yrs of VC experience, previously at Khosla Ventures, Softbank’s China Venture Capital Fund, Co-Founder & Partner at Formation-8)

Boston Strategic Partners, Inc. – Engagement Manager (1/2015 – 11/2019)

Boston Strategic Partners, Inc. is a Global Health Industry Analytics and Communications firm providing consulting services exclusively to the life sciences industry. Worked as an Engagement Manager since Jul. 2018, previously promoted from Senior Consultant and Consultant. Managed projects on Health Economics and Outcomes Research (HEOR) generating real-world data evidence on central nervous system disorders (CNS) disorders for clinical-stage biopharma clients, based on analyses of patient electronic health records (EHR) and claims databases.

Examples of my work in HEOR and the firm’s other practice areas, Business and Clinical Strategy, and Medical Communications, include:

Health Economics and Outcomes Research

  • Led the patient journey analyses on Essential Tremor (ET), identifying a high burden of illness and an unmet need for effective treatments in ET based on real-world claims data analysis
  • Led the identification and graphical visualization of the pharmacologic treatment patterns in Major Depressive Disorder (MDD) and Insomnia for a clinical-stage biopharmaceutical company, highlighting the magnitude of a considerable heterogeneity in current antidepressant use
  • Led the generation of evidence providing insights on antidepressant usage in Post Traumatic Stress Disorder (PTSD) based on relative diagnosis timing with comorbid MDD

Business and Clinical Strategy

  • Assessed the competitive landscape and trends of the biosurgery market, and provided analysis supporting organic and inorganic growth recommendations for a multi-national pharmaceutical company
  • Provided recommendations for developing and promoting the next generation safety software for smart pumps, based on a competitive landscape assessment of the medication management system market
  • Evaluated the commercial opportunity of introducing a next generation opioid dependence drug for a global biopharmaceutical company, examining current and future competitive, reimbursement and regulatory landscapes of the CNS market

Medical Communications

  • Developed a cost-effectiveness abstract supporting a biopharmaceutical company’s efforts in communicating the clinical and economic value of a treatment injection of osteoarthritis of the knee
  • Developed a series of posters communicating findings of the Boston Strategic Partners monthly disease awareness reports for the ISPOR 2019 Annual Meeting, which is the Leading Global Conference for Health Economics and Outcomes Research
  • Created a presentation summary of recent clinical findings for the treatment of CNS disorders, submitted as a journal review in support of the medical communication efforts of a biopharmaceutical company

Other international work experiences as advisor for companies in USA and UK include:

  • VISTAN Health – Strategic Advisor (10/2020 – Present)
    • Providing strategic business development advice to VISTAN, a pioneer of empathetic audio companion that provides vetted insights from doctors, health experts, and survivors at every stage from diagnosis to cancer-free
  • Capital Cell – Business Development Advisor (10/2016 – 12/2017)
    • Provided advice on business development aspects for establishing the first European equity crowdfunding platform for biotech projects
  • Nagel and Partners Ltd – Life Science Strategy Advisor (10/2016 – 12/2017)
    • Supported start-ups and SMEs through business model assessment and development
  • Brain-e-Games – Advisory Board Member (Scientific Advisor) (1/2015 – 2/2016)
    • Developed business model at the initial stages of company formation, focusing on competition analysis and brain games market gap identification
    • Conducted analysis on patient recruitment methodologies followed by clinical research organizations, pharma and biotech companies for Alzheimer’s clinical trials
  • Oxbridge Biotech Roundtable – Analyst (5–7/2014)
    • Designed and launched a global competition for future innovative healthcare ideas for a pharma company
  • Imperial College London – Tender Opportunities Consultant (5/2010 – 6/2012)
    • Mapped the market landscape for a patented Imperial College London technique that substantially improves the aluminum forming process in the automotive sector, obtaining first place among candidates for creating the highest value for Imperial Innovations